ceftaroline fosamil

This medicine is authorised for use in the European Union.


Zinforo is an antibiotic. It is used to treat adults and children (including newborn babies) who have:

  • complicated infections of the skin and soft tissue (tissue below the skin). ‘Complicated’ means that the infection is difficult to treat;
  • community-acquired pneumonia (an infection of the lungs that is caught outside of hospital).

Prescribers should consider official guidance on the appropriate use of antibiotics.

Zinforo contains the active substance ceftaroline fosamil.

This EPAR was last updated on 22/07/2022

Authorisation details

Product details
Agency product number
Active substance
Ceftaroline fosamil
International non-proprietary name (INN) or common name
ceftaroline fosamil
Therapeutic area (MeSH)
  • Community-Acquired Infections
  • Skin Diseases, Infectious
  • Pneumonia
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Pfizer Ireland Pharmaceuticals
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Operations Services Group
County Cork

Product information

01/06/2021 Zinforo - EMEA/H/C/002252 - IB/0060

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:

  • Complicated skin and soft tissue infections (cSSTI)
  • Community-acquired pneumonia (CAP)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings
1 rating
1 rating